REG - AstraZeneca PLC - Directorate Change

AstraZenecaAnnouncement

16/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241216:nRSP1206Qa&default-theme=true

RNS Number : 1206Q  AstraZeneca PLC  16 December 2024

16 December 2024 07:00 GMT

 

 

Non-Executive Board Appointments

 

AstraZeneca PLC announced today that Rene Haas and Birgit Conix have been
appointed as Non-Executive Directors with effect from 1 January 2025 and 1
February 2025 respectively.

 

Birgit will become a member of the Audit Committee on appointment to the
Board.

 

Rene is Chief Executive Officer of Arm. Birgit is Chief Financial Officer of
Sonova. Further biographical details are set out below.

 

Michel Demaré, Chair of AstraZeneca, said "I am confident Rene and Birgit
will be excellent additions to the AstraZeneca Board.  We look forward to
welcoming them as we continue the process of refreshing the Board in
anticipation of four current Non-Executive Directors reaching nine years'
tenure in the coming years.

 

"Rene brings deep and broad knowledge of technology including data science,
computing and AI from his numerous years' experience in the microprocessor,
semiconductor and software engineering industry, and experience of leading a
large Cambridge, UK-based technology company.

 

"Birgit's financial and executive experience through successive CFO roles over
the last decade, together with her 15 years' experience of the pharmaceutical
industry prior to that, will enable her to contribute to the Audit Committee's
and Board's work from the outset.

 

"Both Rene and Birgit bring to AstraZeneca's Board significant international
experience in senior executive roles at large global businesses."

 

Biographical details - Rene Haas

Rene was appointed Chief Executive Officer and to the Arm Board in February
2022.  In September 2023, he led Arm's return to the public markets with the
most valuable IPO of the year.  Prior to becoming CEO, Rene was President of
Arm's IP Product Groups (IPG) from January 2017.  Under his leadership, he
transformed IPG to focus on key solutions for vertical markets with a more
diversified product portfolio and increased investment in the Arm software
ecosystem.  Rene joined Arm in October 2013 as Vice President of Strategic
Alliances and two years later was appointed to the Executive Committee and
named Arm's Chief Commercial Officer in charge of global sales and marketing.

 

Before joining Arm, Rene held several applications management, applications
engineering and product engineering roles, including seven years at NVIDIA as
Vice President and General Manager of its computing products business.  Prior
to NVIDIA, Rene held executive roles at Scintera Networks and Tensilica.

 

In addition to his role as CEO of Arm, Rene also sits on the Boards of Arm
China and SoftBank Group.

 

Rene is based in Silicon Valley, US and also spends significant time in the
major technology centres of the UK, Europe and Asia Pacific.

 

Rene earned his Bachelor of Science in Electrical and Electronics Engineering
from Clarkson University and is a graduate of the Stanford University Graduate
School of Business Executive Education Program.

 

Biographical details - Birgit Conix

Birgit joined Sonova and became Chief Financial Officer and a member of the
Management Board in 2021.  She was previously Chief Financial Officer and
member of the Executive Board of TUI, a global leader in tourism, from 2018 to
2021.  Before joining TUI, she was Chief Financial Officer of the Belgian
media, cable and telecommunications business Telenet Group from 2013 until
2018.  Prior to that, she held various senior positions in finance, strategy
and business operations in the pharmaceuticals and medical devices business
units at Johnson & Johnson, and in finance at Heineken, Tenneco and Reed
Elsevier.

 

In addition to her role as CFO of Sonova, Birgit is a member of the
Supervisory Board of ASML, one of the world's leading manufacturers of
chip-making equipment in the semiconductor industry, where she is Chair of the
ESG Committee and a member of the Audit Committee.

 

Birgit holds an MBA from the Booth School of Business, University of Chicago
and a Master of Science in Business Economics from the University of Tilburg.

 

Except as set out above, no disclosure obligations arise under paragraphs (1)
to (6) of UKLR 6.4.8 R of the UK Financial Conduct Authority's Listing Rules
in respect of these appointments.

 

AstraZeneca (https://www.astrazeneca.com/)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on social media @AstraZeneca
(https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)
 

 

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFFLFADELSEIE